Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 7 | 2018 | 413 | 0.990 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 14 | 0.600 |
Why?
|
| Androgens | 2 | 2010 | 48 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 447 | 0.380 |
Why?
|
| Osteosarcoma | 1 | 2011 | 58 | 0.360 |
Why?
|
| Bone Neoplasms | 2 | 2014 | 126 | 0.360 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 84 | 0.350 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 5 | 0.310 |
Why?
|
| Anilides | 1 | 2008 | 18 | 0.300 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 342 | 0.300 |
Why?
|
| Nitriles | 1 | 2008 | 70 | 0.290 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 1465 | 0.270 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 670 | 0.230 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 28 | 0.220 |
Why?
|
| Radiation Tolerance | 3 | 2024 | 52 | 0.220 |
Why?
|
| Neuropilin-2 | 1 | 2024 | 40 | 0.220 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 67 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2024 | 174 | 0.210 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 663 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2024 | 297 | 0.200 |
Why?
|
| Integrins | 2 | 2014 | 108 | 0.180 |
Why?
|
| Down-Regulation | 2 | 2018 | 319 | 0.160 |
Why?
|
| Oligopeptides | 1 | 2018 | 132 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2008 | 207 | 0.130 |
Why?
|
| Cell Survival | 1 | 2018 | 569 | 0.130 |
Why?
|
| Transfection | 1 | 2018 | 692 | 0.130 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 49 | 0.130 |
Why?
|
| HLA-DP beta-Chains | 1 | 2015 | 2 | 0.120 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 31 | 0.120 |
Why?
|
| RNA Interference | 1 | 2018 | 618 | 0.110 |
Why?
|
| Male | 10 | 2018 | 29814 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 111 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2024 | 3033 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 233 | 0.110 |
Why?
|
| Osteolysis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 29 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 76 | 0.110 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 136 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2011 | 502 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2014 | 373 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 349 | 0.100 |
Why?
|
| Fibronectins | 2 | 2008 | 43 | 0.090 |
Why?
|
| Limb Salvage | 1 | 2011 | 69 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 372 | 0.090 |
Why?
|
| Humans | 11 | 2024 | 63292 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 345 | 0.080 |
Why?
|
| Survival Rate | 1 | 2011 | 850 | 0.080 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2010 | 142 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 172 | 0.080 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 15 | 0.080 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 52 | 0.080 |
Why?
|
| Young Adult | 3 | 2016 | 4683 | 0.070 |
Why?
|
| Adolescent | 3 | 2016 | 6238 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 281 | 0.070 |
Why?
|
| Prognosis | 1 | 2011 | 1750 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2460 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2010 | 985 | 0.060 |
Why?
|
| Integrin beta1 | 1 | 2005 | 32 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2568 | 0.060 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 14 | 0.060 |
Why?
|
| Monophenol Monooxygenase | 1 | 2004 | 6 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 70 | 0.060 |
Why?
|
| Carbohydrate Metabolism | 1 | 2004 | 49 | 0.050 |
Why?
|
| Melanocytes | 1 | 2004 | 76 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2004 | 173 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 212 | 0.050 |
Why?
|
| Adult | 3 | 2016 | 16782 | 0.050 |
Why?
|
| Child | 1 | 2011 | 4522 | 0.050 |
Why?
|
| Female | 4 | 2024 | 32787 | 0.050 |
Why?
|
| Middle Aged | 3 | 2016 | 17549 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 14390 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6629 | 0.040 |
Why?
|
| Mice | 3 | 2024 | 10827 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 19 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 148 | 0.030 |
Why?
|
| Unrelated Donors | 1 | 2015 | 8 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 32 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 2015 | 96 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2015 | 101 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 581 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 20631 | 0.030 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 517 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 60 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 60 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 730 | 0.030 |
Why?
|
| Genotype | 1 | 2015 | 664 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 491 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2014 | 520 | 0.020 |
Why?
|
| Metribolone | 1 | 2011 | 3 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 10 | 0.020 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 9 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 2010 | 19 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 937 | 0.020 |
Why?
|
| Proteomics | 1 | 2010 | 284 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 524 | 0.020 |
Why?
|
| Rhodamines | 1 | 2005 | 20 | 0.010 |
Why?
|
| Calnexin | 1 | 2004 | 5 | 0.010 |
Why?
|
| Mannose | 1 | 2004 | 22 | 0.010 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2004 | 15 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 132 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 139 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2004 | 64 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 449 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 126 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 198 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 99 | 0.010 |
Why?
|
| Protein Transport | 1 | 2004 | 401 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 293 | 0.010 |
Why?
|
| Glucose | 1 | 2004 | 467 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1073 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2152 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 5338 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 5651 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 2607 | 0.010 |
Why?
|